Osteoporosis In postmenopausal women with osteoporosis,<unk>  at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. Breast cancer In studies of breast cancer prevention,<unk>  showed a 79% reduction in breast cancer incidence and an 83% reduction specific incidence of estrogen receptor-positive breast cancers, which is significantly higher than reductions found with the related SERMs tamoxifen and raloxifene. In accordance, a network meta-analysis of SERMs for breast cancer prevention found the highest reduction in risk with<unk>  of all the drugs. The reduction was even greater than that observed with aromatase inhibitors, which have generally been found to confer a greater risk reduction than SERMs.It also has shown promise in ESR1 mutant patients with 'approximately 40% of patients harboring this mutation'.
Lasofoxifene
Bazedoxifene
Raloxifene
Ormeloxifene
Tamoxifen
Endoxifen
Anastrozole
Denosumab